WILMINGTON, Mass., Oct. 26 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (Nasdaq: DUSA), a specialty pharmaceutical company focused on dermatology announced today that it has been named to Deloitte's 2010 Technology Fast 500 list. For the third consecutive year, Deloitte recognized DUSA as one of the Top 500 fastest growing technology, media, telecommunications, life sciences, and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growth during the period 2005-2009. DUSA grew annual revenues by 163% during this period.
"DUSA is honored to receive this recognition from Deloitte for the third year in a row," said Bob Doman, DUSA's President and Chief Executive Officer. "This is a testament to all of the dedicated DUSA employees who, over the years, have contributed to making our Levulan® Photodynamic Therapy (PDT) one of the fastest growing procedures in dermatology."
Levulan PDT is currently approved for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp. AKs are the most frequently diagnosed skin disease by U.S. dermatologists with over 5 million treatment visits per year. Through the first six months of 2010, U.S. Levulan revenue grew 34% over the prior year six months.
Technology Fast 500 Selection and Qualifying Criteria
Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. This ranking is compiled from nominations submitted directly to the Technology Fast 500 website, and public company database research. Technology Fast 500 award winners for 2010 are selected based on percentage fiscal year revenue growth during the five year period from 2005 to 2009.
To be considered, Technology Fast 500 entrants must meet the following criteria:
- Must own proprietary intellectual property or proprietary technology that contributes to a significant portion of the company's operating revenues.
- Base-year operating revenues must be at least $50,000 USD or CD, and current-year operating revenues must be at least $5 million USD or CD.
- Be in business a minimum of five years.
- Be headquartered in North America.
About Actinic Keratoses
Actinic keratoses are rough-textured, dry, scaly patches on the skin caused by excessive exposure to ultraviolet light, such as sunlight. They occur most frequently on sun exposed areas such as the face, scalp, ears, neck, hands and arms. They form on the outermost layer of skin and they can range in color from skin toned to reddish brown. They can also range in size from as small as a pinhead to larger than a quarter.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® PDT technology platform, and other dermatology products. Levulan® Kerastick® for topical solution plus DUSA's BLU-U® blue light photodynamic therapy illuminator is currently approved for the treatment of minimally to moderately thick actinic keratoses of the face or scalp. DUSA also markets other dermatology products, including the BLU-U without Levulan and ClindaReach®. DUSA is based in Wilmington, Mass. Please visit our website at www.dusapharma.com.
SOURCE DUSA Pharmaceuticals, Inc.